Study identifier:D5980R00096
ClinicalTrials.gov identifier:NCT06321731
EudraCT identifier:N/A
CTIS identifier:N/A
Observational Retrospective Study To Describe Characteristics And Evaluate Real-World Outcomes in COPD Patients Initiating Trixeo Aerosphere (budesonide/glycopyrronium bromide/formoterol fumarate) in Spain
Chronic obstructive pulmonary disease (COPD)
N/A
No
-
All
500
Observational
40 Years - 130 Years
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Oct 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
COPD patients initiating BGF COPD patients ≥40 years old initiating BGF (budesonide/glycopyrronium bromide/formoterol fumarate) at least 12 months before start of data collection. | - |